| Literature DB >> 29435428 |
Farhad Shokraneh1, Clive Elliott Adams1.
Abstract
Introduction: Despite years of use of study-based registers for storing reports of randomized controlled trials (RCTs), the methodology used in developing such registers/databases has not been documented. Such registers are integral to the process of scientific reviewing. We document and discuss methodological aspects of the development and use of study-based registers. Although the content is focused on the study-based register of randomized/controlled clinical trials, this work applies to developers of databases of all sorts of studies related to the human, animals, cells, genes, and molecules.Entities:
Keywords: Cochrane collaboration; Randomized controlled trials as topic; Reference-based register; Study-based register; Systematic reviews
Year: 2017 PMID: 29435428 PMCID: PMC5801532 DOI: 10.15171/bi.2017.25
Source DB: PubMed Journal: Bioimpacts ISSN: 2228-5652
Figure 1A study record containing the metadata, data extracted from a trial report, and the location of the data within the report
| Metadata | Data from report(s) | Location | |||
| Study Name* | |||||
| Reference(s) |
Jahanian 2014 | ||||
| Characteristics | Location in PDF** | ||||
| Methods | Allocation: "randomly assigned" no details reported. | 19855PG30C1P3L7 | |||
| Blindness: "double blind" no details reported. | 19855PG30C1P3L3 | ||||
| Design: not reported. | |||||
| Duration: "eight weeks". | 19855PG31C1P2L4 | ||||
| Setting: "Razi Psychiatric Center, Tehran, Iran". | 19855PG30C1P3L5 | ||||
| Participants | Diagnosis: Patients with schizophrenia and tardive dyskinesia (TD) based on DSM-IV-TR diagnosed by psychiatrist. | 19855PG30C1P3L12-13 | |||
| N=40. | 19855PG30C1P3L5 | ||||
| Age: range 18-65 years. | 19855PG30C1P3L17 | ||||
| Sex: not reported. | |||||
| Interventions | 1. Rivastigmine: dose: 1.5 mg twice daily. N=20. | 19855PG30C1P3L7-8 | |||
| 2. Placebo: no details reported. N=20. | 19855PG30C1P3L10 | ||||
| Outcomes | TD symptoms: no improvement (AIMS). | 19855PG31C1P2L5 | |||
| Notes | Sponsorship source: "no financial support". | 19855PG33C2P3L1-2 | |||
| Risk of Bias | |||||
| Bias | Support Statement from Report | ||||
| Random sequence generation | "Randomly". No details. | 19855PG30C1P3L7 | |||
| Allocation concealment | Not reported. | ||||
| Blinding of participants and personnel | "Double blind". No details. | 19855PG30C1P3L3 | |||
| Blinding of outcome assessment | "Double blind". No details. | 19855PG30C1P3L3 | |||
| Incomplete outcome data | Not reported. | ||||
| Selective reporting | None. Registered protocol is available (IRCT2012092910964N1). | 19855PG30C1P3L1 | |||
| Other biases | None known. | ||||
| Outcome | |||||
| Rivastigmine | Placebo | ||||
| Mean | SD | Mean | SD | ||
| AIMS after Intervention | 12.5 | 7.0 | 10.3 | 3.1 | 19855PG32T2 |
* This example study has two references.
** The first 5 digits refer to the file name, PG to pages, C to column, P to page, L to line, and T to Table.
Levels of specialized registers
|
|
| a. Setting the scope of register |
| b. Developing, running, documenting, and saving the search strategies |
| c. De-duplicating and curettage the search results |
| d. Screening the search results |
| e. Developing minimum dataset for each reference record |
| f. Importing the reference records |
| g. Maintaining the reference records |
| h. Locating the full texts of all reference records |
|
|
| a. Developing coding scope and guideline for studies |
| b. Coding or extracting general data from each reference |
| c. Concatenation, merging, and cleaning the study records |
| d. Maintaining and updating the study records |
|
|
| a. Classifying the studies under each review title ready to be done |
| b. Developing a machine-readable dataset for each study |
| c. Extracting all data from each study |